First Trust NYSE Arca Biotechnology Index Fund (FBT)
| Assets | $1.36B |
| Expense Ratio | 0.56% |
| PE Ratio | 17.02 |
| Shares Out | n/a |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +9.75% |
| Volume | 13,491 |
| Open | 146.69 |
| Previous Close | 146.67 |
| Day's Range | 145.92 - 147.21 |
| 52-Week Low | 128.51 |
| 52-Week High | 166.00 |
| Beta | n/a |
| Holdings | 31 |
| Inception Date | Jun 19, 2006 |
About FBT
Fund Home PageThe First Trust NYSE Arca Biotechnology Index Fund (FBT) is an exchange-traded fund that is based on the NYSE Arca Biotechnology index. The fund tracks an equal-weighted index of US biotechnology stocks. FBT was launched on Jun 19, 2006 and is issued by First Trust.
Top 10 Holdings
38.31% of assets| Name | Symbol | Weight |
|---|---|---|
| Amgen Inc. | AMGN | 4.11% |
| Neurocrine Biosciences, Inc. | NBIX | 4.11% |
| Sarepta Therapeutics, Inc. | SRPT | 4.05% |
| Regeneron Pharmaceuticals, Inc. | REGN | 4.02% |
| Exelixis, Inc. | EXEL | 3.93% |
| Seagen Inc. | SGEN | 3.80% |
| Ionis Pharmaceuticals, Inc. | IONS | 3.75% |
| BioMarin Pharmaceutical Inc. | BMRN | 3.53% |
| BioNTech SE | BNTX | 3.51% |
| Vertex Pharmaceuticals Incorporated | VRTX | 3.50% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| 2021-12-30 | $2.214 | 2022-01-10 |
| 2015-09-23 | $0.0197 | 2015-09-30 |
| 2015-06-24 | $0.0649 | 2015-06-30 |
| 2015-03-25 | $0.0476 | 2015-03-31 |
| 2014-12-23 | $0.0524 | 2014-12-31 |
News
Here are the top-performing ETFs in first half of 2023 as crypto-related funds soar
Hello! This week's ETF Wrap looks at top performers in the first half of 2023, as well as flows, as stocks rally and crypto-related funds jump so far this year.
Will Biotech ETFs Benefit from Biogen's New Alzheimer's Drug?
Biotech investors may have reason to celebrate this week, as the FDA approved Biogen's Alzheimer's disease drug Aducanumab on Monday, ushering in the first medication to be allowed by U.S. regulators ...
3 ETFs For AstraZeneca's $39B Alexion Pharmaceuticals Takeover
The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a $39-billion takeover of Alexio...
Can't Get Enough Biotech Exposure in Your Portfolio?
As coronavirus cases start to tick upwards once more, the race to create a vaccine will only intensify, boding well for the biotechnology sector. ETF investors may want to keep an eye on biotech funds...
Biotech ETFs at multi-week highs, extending winning streak
Biotechnology exchange-traded funds outperformed Tuesday as investors focused on next-generation solutions to the coronavirus and more. The ARK Genomic Revolution ETF was up 2.2% in the early afternoo...
Biotech ETFs at two-week highs on upbeat vaccine news
Biotech exchange-traded funds got a bounce Friday from bullish news on coronavirus treatments. The ALPS Medical Breakthroughs ETF , the ARK Genomic Revolution ETF , and the First Trust NYSE Arca Biote...
Encouraging Election Year History for this Biotech ETF
Healthcare is one of the most politically sensitive sectors and that sensitivity is on full display in recent weeks with biotechnology ETFs, including the First Trust NYSE Arca Biotechnology Index Fun...
Election History Says Buy Biotech Dip
Biotechnology exchange-traded funds were hot until they weren't. History indicates recent weakness in the previously high-flying group be a symptom of election year jitters and investors shouldn't ign...
Post-Pandemic Stars Could Align For This Biotech ETF
These days, it's not hard to find winners among health care exchange-traded funds and that's true of both established and rookie players.
Biotech ETFs Still Promising Despite Hydroxychloroquine Trial
In the continuing quest to find a vaccine for the coronavirus, the World Health Organization announced Wednesday it is dropping hydroxychloroquine, the malaria drug backed by President Trump, who clai...
There’s Still Plenty of Opportunity for Biotech Post-Coronavirus
While the Coronavirus pandemic continues dominating healthcare sector headlines, investors shouldn’t fret that biotechnology ETFs will be left vulnerable when the virus is finally vanquished. That’s g...
ACADIA Pharmaceuticals Help Lift Biotech ETFs
While the rest of the biotechnology sector remained depressed along with the broader markets, related exchange traded funds found strength from an unexpected surge in ACADIA Pharmaceuticals (NasdaqGS:...
Biotech stocks fall after Trump promises executive order drug prices
CNBC's Meg Tirrell reports on the dip in biotech stocks after President Donald Trump promised that an executive order on drug prices is coming.